Back

Qualia NAD+(R) Increases NAD+, Improves Well-Being, and Alleviates Aging Symptoms: A Randomized, Double-Blind, Placebo-Controlled Study

Blomquist, S.; Kelly, G.; Adaes, S.; Ardagh, A.; Ramer, S.; Scuba, W.

2025-05-16 nutrition
10.1101/2025.05.14.25327611 medRxiv
Show abstract

A key factor in aging and many age-related diseases is the decline in nicotinamide adenine dinucleotide (NAD+) levels. Preclinical studies demonstrate promising results for NAD+ boosting in improving conditions of disease or aging. However, only a limited number of human studies have shown meaningful improvements in physiological function or quality of life with NAD+ boosting supplements. This randomized, double-blind, placebo-controlled study (Clinicaltrails.gov identifier: NCT06505967) investigated the impact of Qualia NAD+(R), a novel NAD+ supporting nutraceutical containing nicotinamide riboside (NR) and a variety of synergistic vitamins, minerals, and botanicals, on blood NAD+ levels and healthy aging, as assessed by quality of life surveys. MethodsStudy participants were randomly allocated to consume either Qualia NAD+ or placebo for 28 days. NAD+ levels were measured at baseline and study end using a validated, self-administered, dried blood spot assay. Quality of life measures were assessed weekly. Independent samples t-tests were used to compare NAD+ levels between study arms. Questionnaire data were compared using linear mixed-effects regression modeling. ResultsSixty-three healthy adults (n = 28 Qualia NAD+, n=35 placebo) enrolled in the study and had their NAD+ levels assessed. Qualia NAD+ increased NAD+ levels by 67% compared to 4% with placebo (p < 0.001). Qualia NAD+ improved emotional well-being versus placebo at multiple timepoints (p < 0.05). Aging female symptoms improved in overall and somatic categories at day 28 (p < 0.05). No improvements in aging symptoms were observed for males. ConclusionsQualia NAD+ increased NAD+ levels, enhanced quality of life in all participants, and alleviated some aging symptoms in females greater than placebo. The increase in NAD+ levels with Qualia NAD+ was greater than in most previous clinical trials of NAD+ supporting products at similar dosing, suggesting potential synergy between NR and the complementary nutrients in the product.

Matching journals

The top 5 journals account for 50% of the predicted probability mass.

50% of probability mass above

"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.